Story perspectives

AstraZeneca Phase 3 shows tozorakimab cuts COPD exacerbations 30%

9/9/2026

Summary

AstraZeneca Cuts COPD Exacerbations

AstraZeneca’s Phase 3 trials showed tozorakimab cut COPD exacerbations by roughly 30%.
Patients with high eosinophil counts experienced a 43% reduction in flare-ups.
Those with lower eosinophil levels saw a 23% decrease in exacerbations.
The drug also lowered lung mucus plugging and was well tolerated.
U.S. FDA granted priority review, with a decision expected in Q1 2027 after Barcelona presentation.

Summary

AstraZeneca Fast-Tracks

The FDA granted Fast Track designation to tozorakimab for COPD in December 2024 and for viral disease in November 2023.
The PROSPERO extension trial enrolled 1,713 patients to evaluate severe exacerbations over 104 weeks.
A priority review voucher anticipates a PDUFA action date in the first quarter of 2027.
AstraZeneca is pursuing regulatory approval for tozorakimab in the European Union and China.

Summary

AstraZeneca Raises Forecast

AstraZeneca raised tozorakimab’s peak sales forecast to over $5 billion targeting its $80 billion 2030 revenue goal.
The drug could address 16-26 million U.S. COPD patients, many of whom remain undiagnosed.
Dupixent and Nucala treat only high-eosinophil COPD, leaving low-eosinophil patients without options.
Analysts say lacking head-to-head trials with existing biologics creates payer adoption uncertainty.
Investors expect the blockbuster could lift earnings and strengthen AstraZeneca’s chronic-disease pipeline.

History

Historical Context

After Tanox partnered with Ciba-Geigy in 1990 and secured the first FDA IND for an anti-IgE antibody in 1991, the humanized product omalizumab received U.S. approval in June 2003 and EU authorization in October 2005. Its success, despite early UK cost concerns of over £250 per vial, paved the way for AstraZeneca’s tozorakimab to pursue FDA fast-track review in 2024.

1 of 4

AstraZeneca Cuts COPD Exacerbations

AstraZeneca’s Phase 3 trials showed tozorakimab cut COPD exacerbations by roughly 30%.
Patients with high eosinophil counts experienced a 43% reduction in flare-ups.
Those with lower eosinophil levels saw a 23% decrease in exacerbations.
The drug also lowered lung mucus plugging and was well tolerated.
U.S. FDA granted priority review, with a decision expected in Q1 2027 after Barcelona presentation.

1 / 4